The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:
----------
Cizzle Biotechnology Holdings PLC - London diagnostics developer company engaged in developing a blood test for the early detection of the different forms of lung cancer - Reports operating loss before tax in 2023 widens to £1.8 million from £963,000 a year prior. This reflects increase in administrative expenses to £1.8 million from £963,000. Loss per basic and diluted share is 0.5 pence compared to 0.3p. No revenue declared, unchanged. Intends that the group’s initial commercial product will be based on a platform that can be readily performed by hospitals and reference laboratories. Envisages that potential follow-on products could be immunoassay kits and a point of
care test provided by primary health care providers. Feels well placed to meet key milestones planned for the launch of its first commercial product. Continues discussions with existing partners in the US and China to develop its future opportunities in global markets.
----------
Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Says revenue in 2023 more than doubles to £23.2 million from £9.7 million. Cost of sales multiplies to £12.0 million from £2.4 million. Pretax loss narrows to £27.3 million from £41.6 million. Chair Eliot Forster comments: ‘The clinical momentum demonstrated by AVA6000 during the reporting period and into the post-period has significantly enhanced our confidence in AVA6000 and the broader pre/CISION platform.’
----------
Poolbeg Pharma PLC - London-based clinical-stage biopharmaceutical company - In 2023, says pretax loss narrows to £4.5 million from £4.8 million a year prior. Nil revenue, unchanged. Administrative expenses tick up to £3.4 million from £3.1 million but research and development costs fall to £1.7 million from £2.2 million. Loss per share totals 0.79 pence compared to 0.94p before. Further, enters exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a muco-adherent formulation of Pentoxifylline for the treatment of oral ulcers in patient’s suffering from Behcet’s disease. Notes a Phase 2 trial has successfully completed, demonstrating superiority over standard of care. Plans to continue due diligence throughout the term of the agreement which will include engagement with Silk Road Therapeutics to ascertain the clinical approval pathway.
----------
Digital 9 Infrastructure PLC - investor in internet infrastructure, such as data centres and subsea fibre - In 2023, reports net asset value falls to 79.33 pence from 109.76p a year prior. Halves dividend to 3p per share from 6p. Loss per share is 27.43p compared to EPS of 11.09p. Debt increases to £544.8 million from £494.2 million. Explains NAV decline was primarily due to a £179.3 million change in the fair value of the investment portfolio. The latter included £32.8 million of foreign exchange movements, which primarily related to Verne Global. Also reflects increased costs, such as interest expenses and professional fees. In March, Digital 9 completed the sale of its entire stake in the Verne Global group of companies to funds managed or advised by Ardian France SA for up to $575 million, around £450 million.
----------
RBG Holdings PLC - London-based legal and professional services firm - In 2023, says revenue falls 13% to £39.2 million from £44.9 million a year prior, while pretax loss widens to £11.4 million from £2.1 million. Basic loss per share from continuing operations is 11.58 pence compared to 1.73p. Calls 2023 a ‘very challenging year.’ Says trading in the first quarter of 2024 has been in line with expectations. Expresses optimism that 2023 marked the end of the pivot from the group’s previous strategy and that there are opportunities for the group to grow.
----------
Smarttech247 Group PLC - Cork, Ireland-based artificial intelligence-enhanced cybersecurity services provider - In the six months to January, reports revenue of €5.4 million, up 17% from €4.6 million a year prior. Operating expenses rise 58% to €4.1 million from €2.6 million. Pretax loss widens to €601,000 from €450,000. Basic and diluted earnings per share are €0.53 compared to €0.86.
Chief Executive Raluca Saceanu comments: ‘As the cybersecurity landscape continues to evolve and we see new threats daily, we are signing new contracts, expanding our business pipeline and adapting our product offerings and technology to ensure we can meet our clients’ vital cybersecurity needs.’ Adds: ‘Positive about the prospects for the second half of FY2024 and for the year as a whole.’
----------
Kelso Group Holdings PLC - investor in ’undervalued’ London-listed companies - Swings to pretax profit of £2.0 million in 2023 from loss of £289,324 a year prior. Revenue totals £2.6 million compared to zero. Administrative expenses rise to £460,430 from £287,857. Earnings per diluted share are 0.56 pence compared to LPS of 0.61p. Chief Executive John Goold says: ‘We are pleased to deliver Kelso’s first set of financial results, highlighting the successful implementation of its strategy to assist UK listed companies unlock their true value. Kelso’s Board is committed to the success of the company and continues to actively review new investment opportunities.’ ‘The UK stock market remains challenging but we hope initiatives like the new British ISA will help stimulate demand, in particular for the UK’s smaller companies which remain lowly valued,’ company says.
----------
Northcoders Group PLC - Manchester-based software coding training provider - In 2023, reports revenue rises 27% to a record £7.1 million from £5.6 million a year prior driven by geographic expansion and entry into new disciplines. Despite this, swings to pretax loss of £1.2 million from £346,429 profit. Cost of sales increases to £2.7 million from £1.7 million, while amortisation and impairment charges near treble to £234,225 from £85,167. Adjusted loss per share is 4.81 pence compared to EPS of 8.02p. Reports record growth in numbers of individuals trained, increasing to 2,852 from 1,685 the year before. Says both business-to-customer and business-to-business divisions start 2024 strongly, with record B2C applications and a growing pipeline for B2B contracts. Notes revenue access and contracted visibility already reaches £8.3 million for 2024. Overall, 2024 trading is in line with expectations.
----------
Copyright 2024 Alliance News Ltd. All Rights Reserved.
